

# PathTracer: High-sensitivity detection of differential pathway activity in tumours

**Ståle Nygård<sup>1,2,\*</sup>, Ole Christian Lingjærde<sup>1,3,4,\*</sup>, Carlos Caldas<sup>5</sup>, Eivind Hovig<sup>1,6</sup>, Anne-Lise Børresen-Dale<sup>3, °</sup>, Aslaug Helland<sup>3,7,8</sup>, and Vilde D. Haakensen<sup>3,7,†</sup>**

<sup>1</sup>Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway

<sup>2</sup>Bioinformatics core facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

<sup>3</sup>Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

<sup>4</sup>KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Norway

<sup>5</sup>Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK

<sup>6</sup>Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway


<sup>7</sup>Department of Oncology, Oslo University Hospital, Oslo, Norway

<sup>8</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway

\*These authors contributed equally to this study

†Corresponding author [vilde.haakensen@gmail.com](mailto:vilde.haakensen@gmail.com)

**Histogram of PDS vs PTS correlation**



Histogram of correlation between pathifier deregulation scores (PDS) and PathTracer scores (PTS) based on the metabric breast cancer dataset.